0Y5E Stock Chart & Stats
$14.38
$0.05(0.49%)
At close: 4:00 PM EDT
$14.38
$0.05(0.49%)
Day’s Range― - ―
52-Week Range$9.28 - $23.57
Previous CloseN/A
Volume701.00
Average Volume (3M)3.49K
Market Cap
$2.07B
Enterprise Value$4.45K
Total Cash (Recent Filing)$399.70M
Total Debt (Recent Filing)$3.29B
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield7.88%
Share Statistics
EPS (TTM)-12.51
Shares Outstanding138,769,240
10 Day Avg. Volume1,645
30 Day Avg. Volume3,491
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.45
P/FCF Ratio13.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside18.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.2
Revenue Forecast (FY)$4.05B
Bulls Say, Bears Say
Bulls Say
Market Share GainsOutperforming declining OTC categories in both the U.S. and Europe indicates Perrigo is strengthening retailer and consumer relevance. Share gains can support more durable volume growth, improve negotiating position with retail customers, and provide a foundation for future innovation-led expansion.
Positive Free Cash FlowPositive operating and free cash flow provide internal funding for debt reduction, product investment, and shareholder returns despite reported accounting losses. Sustained cash generation would improve financial flexibility and help Perrigo execute its portfolio and operational improvement initiatives.
Operational Improvement PotentialA sizable, multi-year savings program could help offset category pressure and rebuild margins if execution remains on track. The opportunity is strategically important because recurring cost reductions would improve earnings resilience rather than relying only on temporary benefits or favorable comparisons.
Bears Say
Shrinking RevenuePersistent sales contraction indicates that category softness, retailer inventory reductions, and portfolio changes are weighing on demand and volumes. Continued top-line pressure can reduce operating leverage, constrain innovation funding, and make margin recovery more difficult across the business.
Margin And Earnings CompressionBroad gross-margin and earnings declines show that current operating pressure is reaching profitability, not just revenue. Lower margins reduce the company’s ability to absorb weaker volumes and raise the execution burden for planned savings, innovation, and service-level improvements.
Elevated LeverageA substantial debt balance limits financial flexibility while profitability remains weak and margins are under pressure. Although asset-sale proceeds have reduced borrowings, continued leverage can constrain capital allocation and leave less capacity to manage operational setbacks or fund growth.
Perrigo Company News
0Y5E FAQ
What was Perrigo Company plc’s price range in the past 12 months?
Perrigo Company plc lowest share price was $9.28 and its highest was $23.57 in the past 12 months.
What is Perrigo Company plc’s market cap?
Perrigo Company plc’s market cap is $2.07B.
When is Perrigo Company plc’s upcoming earnings report date?
Perrigo Company plc’s upcoming earnings report date is Nov 11, 2026 which is in 64 days.
How were Perrigo Company plc’s earnings last quarter?
Perrigo Company plc released its earnings results on Aug 05, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.388 by $0.112.
Is Perrigo Company plc overvalued?
According to Wall Street analysts Perrigo Company plc’s price is currently Undervalued.
Does Perrigo Company plc pay dividends?
Perrigo Company plc pays a Quarterly dividend of $0.29 which represents an annual dividend yield of 7.88%. See more information on Perrigo Company plc dividends here
What is Perrigo Company plc’s EPS estimate?
Perrigo Company plc’s EPS estimate is 0.52.
How many shares outstanding does Perrigo Company plc have?
Perrigo Company plc has 138,769,240 shares outstanding.
What happened to Perrigo Company plc’s price movement after its last earnings report?
Perrigo Company plc reported an EPS of $0.5 in its last earnings report, beating expectations of $0.388. Following the earnings report the stock price went up 24.135%.
Which hedge fund is a major shareholder of Perrigo Company plc?
Currently, no hedge funds are holding shares in GB:0Y5E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perrigo Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (18.22% Upside)
$17.00 (18.22% Upside)
Blogger Sentiment
Bullish
GB:0Y5E Sentiment 80%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.89%
12-Months-Change
Fundamentals
Return on Equity
7.88%
Trailing 12-Months
Asset Growth
-24.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
0Y5E Company Deck
0Y5E Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress and strategic actions against ongoing top-line and margin pressures. Positive indicators include market share gains, substantial service-level improvements, a recovering Infant Formula business (+23% sales, +$60M operating income), acceleration of a scalable innovation pipeline, targeted cost-savings ($80–$100M program) and the use of $359M divestiture proceeds to reduce debt. Offsetting these positives were a 3%+ decline in net sales, 250 basis points of gross margin compression, notable retailer destocking (≈1.8% headwind), specialty segment weakness and an expected ~$0.60 EPS headwind in 2026 from under-absorption. Management maintained full-year guidance and emphasized that results are weighted to a stronger second half, signaling cautious optimism but acknowledging remaining execution and demand risks.View all GB:0Y5E earnings summaries0Y5E Stock 12 Month Forecast
Average Price Target
$17.00
▲(18.22% Upside)
Technical Analysis
Viatris
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Indivior
―
Amneal Pharmaceuticals
―